Stock Research for ALNY


Featured Broker: Ally Invest

Get the due diligence for another stock.


ALNY Stock Chart & Research Data

The ALNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ALNY Due diligence Resources & Stock Charts

The ALNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALNY Detailed Price Forecast - CNN Money CNN View ALNY Detailed Summary - Google Finance
Yahoo View ALNY Detailed Summary - Yahoo! Finance Zacks View ALNY Stock Research & Analysis -

Stock Analysis

TradeIdeas View ALNY Trends & Analysis - Trade-Ideas Barrons View ALNY Major Holders - Barrons
NASDAQ View ALNY Call Transcripts - NASDAQ Seeking View ALNY Breaking News & Analysis - Seeking Alpha
Spotlight View ALNY Annual Report - OTC Report View ALNY OTC Short Report -
TradeKing View ALNY Fundamentals - TradeKing Charts View ALNY SEC Filings - Bar Chart
WSJ View Historical Prices for ALNY - The WSJ Morningstar View Performance/Total Return for ALNY - Morningstar
MarketWatch View the Analyst Estimates for ALNY - MarketWatch CNBC View the Earnings History for ALNY - CNBC
StockMarketWatch View the ALNY Earnings - StockMarketWatch MacroAxis View ALNY Buy or Sell Recommendations - MacroAxis
Bullish View the ALNY Bullish Patterns - American Bulls Short Pains View ALNY Short Pain Metrics -

Social Media Mentions

StockTwits View ALNY Stock Mentions - StockTwits PennyStocks View ALNY Stock Mentions - PennyStockTweets
Twitter View ALNY Stock Mentions - Twitter Invest Hub View ALNY Investment Forum News - Investor Hub
Yahoo View ALNY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALNY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ALNY - Insider Cow View Insider Transactions for ALNY - Insider Cow
CNBC View ALNY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALNY - OTC Markets
Yahoo View Insider Transactions for ALNY - Yahoo! Finance NASDAQ View Institutional Holdings for ALNY - NASDAQ

Stock Charts

FinViz View ALNY Stock Insight & Charts - StockCharts View ALNY Investment Charts -
BarChart View ALNY Stock Overview & Charts - BarChart Trading View View ALNY User Generated Charts - Trading View

Latest Financial News for ALNY

Top 10 Healthcare Stories of 2018
Posted on Thursday December 13, 2018

New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.

Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
Posted on Thursday December 13, 2018

NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Posted on Monday December 10, 2018

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

Alnylam Announces Settlement of Litigation with Silence Therapeutics
Posted on Sunday December 09, 2018

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multiple countries. Under terms of the global settlement, Silence will receive a low royalty on annual net sales of ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent through 2023. Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline).

Stock Market & Investing Books

Enter a stock symbol to view the stock details.